After an initial decrease, platelet and neutrophil counts stabilized with Jakafi® (ruxolitinib)1
In REACH2, no clinically meaningful differences in platelet and neutrophil counts were observed over time in patients receiving Jakafi vs those in the control group1

- aPlot shows boxes (25th-75th percentiles) with median as horizontal line. The dots in the boxes and joint lines represent the mean values. Whiskers (vertical lines) extend to the 10th-90th percentiles.1
- bValues outside this range are not displayed.1

- aPlot shows boxes (25th-75th percentiles) with median as horizontal line. The dots in the boxes and joint lines represent the mean values. Whiskers (vertical lines) extend to the 10th-90th percentiles.1
- bValues outside this range are not displayed.1
REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
Reference: 1. Data on file. Incyte Corporation. Wilmington, DE.